Expression pattern and prognostic implication of SALL4 gene in myeloid leukemias: a case-control study

References

• Pollyea DA, Gutman JA, Gore L, et al. Targeting acute myeloid leukemia stem cells: a review and principles for the development of clinical trials. Haematologica. 2014;99:1277–1284.
   PubMed Web of Science ®Google Scholar
• Merante S, Orlandi E, Bernasconi P, et al. Outcome of four patients with chronic myeloid leukemia after imatinib mesylate discontinuation. Haematologica. 2005;90:979–981.
   PubMed Web of Science ®Google Scholar
• Corbin AS, Agarwal A, Loriaux M, et al. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J Clin Invest. 2011;121:396–409.
   PubMed Web of Science ®Google Scholar
• Gao C, Kong NR, Chai L. The role of stem cell factor SALL4 in leukemogenesis. Crit Rev Oncog. 2011;16:117–127.
   PubMedGoogle Scholar
• Ma Y, Cui W, Yang J, et al. SALL4, a novel oncogene, is constitutively expressed in human acute myeloid leukemia (AML) and induces AML in transgenic mice. Blood. 2006;108:2726–2735.
   PubMed Web of Science ®Google Scholar
• Shen Q, Liu S, Hu J, et al. The differential expression pattern of BMI-1, SALL4 and ABCA3 genes in myeloid leukemia. Cancer Cell Int. 2012;12:42.
   PubMed Web of Science ®Google Scholar
• Cui W, Kong NR, Ma Y, et al. Differential expression of the novel oncogene, SALL4, in lymphoma, plasma cell myeloma, and acute lymphoblastic leukemia. Mod Pathol. 2006;19:1585–1592.
   PubMed Web of Science ®Google Scholar
• Kobayashi D, Kuribayshi K, Tanaka M, et al. SALL4 is essential for cancer cell proliferation and is overexpressed at early clinical stages in breast cancer. Int J Oncol. 2011;38:933–939.
   PubMed Web of Science ®Google Scholar
• Kobayashi D, Kuribayashi K, Tanaka M, et al. Overexpression of SALL4 in lung cancer and its importance in cell proliferation. Oncol Rep. 2011;26:965–970.
   PubMed Web of Science ®Google Scholar
• Forghanifard MM, Moghbeli M, Raeisossadati R, et al. Role of SALL4 in the progression and metastasis of colorectal cancer. J Biomed Sci. 2013;20:6.
   PubMed Web of Science ®Google Scholar
• Fassina A, Cappellesso R, Guzzardo V, et al. Epithelial-mesenchymal transition in malignant mesothelioma. Mod Pathol. 2012;25:86–99.
   PubMed Web of Science ®Google Scholar
• Zhang X, Yuan X, Zhu W, et al. SALL4: an emerging cancer biomarker and target. Cancer Lett. 2015;357:55–62.
   PubMed Web of Science ®Google Scholar
• Cheng J, Gao J, Shuai X, et al. Oncogenic protein SALL4 and ZNF217 as prognostic indicators in solid cancers: meta-analysis of individual studies. Oncotarget. 2016;7:24314–24325.
   PubMedGoogle Scholar
• Tatetsu H, Kong NR, Chong G, et al. SALL4, the missing link between stem cells, development and cancer. Gene. 2016;584:111–119.
   PubMed Web of Science ®Google Scholar
• Wang F, Guo Y, Chen Q, et al. Stem cell factor SALL4, a potential prognostic marker for myelodysplastic syndromes. J Hematol Oncol. 2013;6:73.
   PubMed Web of Science ®Google Scholar
• Yong KJ, Li A, Ou WB, et al. Targeting SALL4 by entinostat in lung cancer. Oncotarget. 2016;7:75425–75440.
   PubMedGoogle Scholar
• Yuan X, Zhang X, Zhang W, et al. SALL4 promotes gastric cancer progression through activating CD44 expression. Oncogenesis. 2016;5:e268.
   PubMed Web of Science ®Google Scholar
• Nicolè L, Sanavia T, Veronese N, et al. Oncofetal gene SALL4 and prognosis in cancer: A systematic review with meta-analysis. Oncotarget. 2017;8:22968–22979.
   PubMedGoogle Scholar
• Döhner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European Leukemia Net. Blood. 2010;115:453–474.
   PubMed Web of Science ®Google Scholar
• Cross NC, White HE, Colomer M, et al. Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia. Leukemia. 2015;29:999–1003.
   PubMed Web of Science ®Google Scholar
• Vardiman JW, Thiele J, Arber DA, Brunning RD, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114:937–951.
   PubMed Web of Science ®Google Scholar
• Lo-Coco F, Avvisati G, Vignetti M, Italian GIMEMA Cooperative Group, et al. Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group. Blood. 2010;116:3171–3179.
   PubMed Web of Science ®Google Scholar
• Baccarani M, Deininger MW, Rosti G, et al. European Leukemia Net recommendations for the management of chronic myeloid leukemia. Blood. 2013;122:872–884.
   PubMed Web of Science ®Google Scholar
• Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008;3:1101–1108.
   PubMed Web of Science ®Google Scholar
• Moellering RE, Cornejo M, Davis TN, et al. Direct inhibition of the NOTCH transcription factor complex. Nature. 2009;462:182–188.
   PubMed Web of Science ®Google Scholar
• Huntly BJ, Gilliland DG. Leukaemia stem cells and the evolution of cancer-stem-cell research. Nat Rev Cancer. 2005;5:311–321.
   PubMed Web of Science ®Google Scholar
• Guzman ML, Allan JN. Concise review: leukemia stem cells in personalized medicine. Stem Cells. 2014;32:844–851.
   PubMed Web of Science ®Google Scholar
• Gao C, Kong NR, Li A, et al. SALL4 is a key transcription regulator in normal human hematopoiesis. Transfusion. 2013;53:037–049.
   Web of Science ®Google Scholar
• Mei K, Liu A, Allan RW, et al. Diagnostic utility of SALL4 in primary germ cell tumors of the central nervous system: a study of 77 cases. Mod Pathol. 2009;22:1628–1636.
   PubMed Web of Science ®Google Scholar
• Chen Q, Qian J, Lin J, et al. Expression of SALL4 gene in patients with acute and chronic myeloid leukemia. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2013;21:315–319.
   PubMedGoogle Scholar
• Jeong HW, Cui W, Yang Y, et al. SALL4, a stem cell factor, affects the side population by regulation of the ATP-binding cassette drug transport genes. PloS One. 2011;6:e18732.
   PubMed Web of Science ®Google Scholar
• Wang F, Gao C, Lu J, et al. Leukemic survival factor SALL4 contributes to defective DNA damage repair. Oncogene. 2016;35:6087–6095.
   PubMed Web of Science ®Google Scholar
• Lu J, Ma Y, Kong N, et al. Dissecting the role of SALL4, a newly identified stem cell factor, in chronic myelogenous leukemia. Leukemia. 2011;25:1211–1213.
   PubMed Web of Science ®Google Scholar